Acorda Therapeutics (NASDAQ:ACOR) has been upgraded from Neutral to Overweight in a report by JPMorgan today.
- Updated: November 30, 2016
JPMorgan has upgraded Acorda Therapeutics (NASDAQ:ACOR) from Neutral to Overweight in a statement released on 11/30/2016.
On Wednesday January 06, 2016, Aegis Capital released a statement on Acorda Therapeutics (NASDAQ:ACOR) raised the target price from $40.00 to $52.00. At the time, this suggested an upside of 0.26%.
Displaying a price of $20.65, Acorda Therapeutics (NASDAQ:ACOR) traded 0.48% higher on the day. With the last close down -12.92% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the same period. Acorda Therapeutics has recorded a 50-day average of $19.64 and a two hundred day average of $23.83. Volume of trade was down over the average, with 274,569 shares of ACOR changing hands under the typical 639,605
Recent Performance Chart
Acorda Therapeutics has a with a one year low of $16.40 and a one year high of $43.63 ACOR’s total market value is presently $0.
A total of 5 firms have issued a report on the stock. 1 firm rating the stock a strong buy, 3 brokers rating the stock a buy, 4 analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $47.20.
Brief Synopsis About Acorda Therapeutics (NASDAQ:ACOR)
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson's disease, chronic post-stroke walking deficits and migraine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.